Retatrutide Improves Liver Inflammation in Diet-Induced Steatohepatitis Mouse Model
Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge.
Background
Steatohepatitis, also known as MASH (metabolic dysfunction-associated steatohepatitis), is a severe form of non-alcoholic fatty liver disease (NAFLD). It involves excessive fat accumulation, inflammation, and liver damage, potentially progressing to cirrhosis and liver cancer. With no approved pharmacological treatments, steatohepatitis is a growing global health concern. This study addresses the critical knowledge gap regarding the therapeutic potential of novel multi-receptor agonists like Retatrutide in mitigating diet-induced steatohepatitis.